www.exelixis.com Open in urlscan Pro
35.193.127.16  Public Scan

Form analysis
4 forms found in the DOM

GET /

<form role="search" method="get" class="et-search-form" action="/"><input type="text" class="et-search-field" placeholder="Search" name="s"></form>

GET /

<form role="search" method="get" class="et-search-form" action="/"><input type="text" class="et-search-field" placeholder="Search" name="s"></form>

GET https://www.exelixis.com/

<form role="search" method="get" class="et-search-form" action="https://www.exelixis.com/">
  <input type="text" class="et-search-field" placeholder="Search …" value="" name="s" title="Search for:"> <input type="submit" value="Search" class="search-btn">
</form>

GET /

<form role="search" method="get" class="et-search-form" action="/"><input type="text" class="et-search-field" placeholder="Search" name="s"></form>

Text Content

 * Careers
 * Contact Us
 * 

 * Our Story
   Mission Leadership Board of Directors Collaborations
 * Medicines
   Our Medicines Access
 * Research & Development
   Research and Development Pipeline
   * Pipeline Overview
   * Early-Stage Compounds
   * Cabozantinib Pipeline
   * Other Partnered Programs
   Clinical Trials
 * Impact
   Why Cancer? Patient Stories Grants & Giving Corporate Responsibility
   Environmental, Social & Governance Statement on COVID-19
 * Investors & Media
   Investors Overview News and Events
   * Press Releases
   * Event Calendar
   * Media Resources
   Stock Information
   * Stock Quote & Chart
   * Historical Price Lookup
   * Investment Calculator
   * Analyst Coverage
   * Earnings Estimates
   Financial Information
   * Annual Reports
   * SEC Filings
   * Interactive Analyst Center
   Investor Resources
   * Investor FAQs
   * Information Request
   Corporate Governance
   * Corporate Governance Documents and Information
   * Management
   * Board of Directors
   * Committee Composition and Charters
   Contact IR
 * 

Select Page
 * Our Story
   * Mission
   * Leadership
   * Board of Directors
   * Collaborations
 * Medicines
   * Our Medicines
   * Access
 * Research & Development
   * Research and Development
   * Pipeline
     * Pipeline Overview
     * Early-Stage Compounds
     * Cabozantinib Pipeline
     * Other Partnered Programs
   * Clinical Trials
 * Impact
   * Why Cancer?
   * Patient Stories
   * Grants & Giving
   * Corporate Responsibility
   * Environmental, Social & Governance
   * Statement on COVID-19
 * Investors & Media
   * Investors Overview
   * News and Events
     * Press Releases
     * Event Calendar
     * Media Resources
   * Stock Information
     * Stock Quote & Chart
     * Historical Price Lookup
     * Investment Calculator
     * Analyst Coverage
     * Earnings Estimates
   * Financial Information
     * Annual Reports
     * SEC Filings
     * Interactive Analyst Center
   * Investor Resources
     * Investor FAQs
     * Information Request
   * Corporate Governance
     * Corporate Governance Documents and Information
     * Management
     * Board of Directors
     * Committee Composition and Charters
   * Contact IR
 * 
 * Careers
 * Contact Us
 * 




EXPERIENCE
MORE

of what matters most.
Cancer is our cause.
Learn More


SMART DRUG DESIGN

We strive to develop best-in-class medicines that target multiple pathways and
work in combination regimens.
Learn More


DEVELOPMENT PIPELINE

Explore our broad clinical development program.
Learn More


ACCELERATING INNOVATION THROUGH PARTNERSHIP

High-impact relationships maximize results and expand possibilities.
Learn More
1234


EXPERIENCE MORE

of what matters most.
Cancer is our cause.
Learn More


SMART DRUG DESIGN

We strive to develop best-in-class medicines that target multiple pathways and
work in combination regimens.
Learn More


DEVELOPMENT PIPELINE

Explore our broad clinical development program.
Learn More


ACCELERATING INNOVATION THROUGH PARTNERSHIP

High-impact relationships maximize results and expand possibilities.
Learn More
1234


EXELIXIS EXPANDS EAST

Learn more about open roles and career opportunities to innovate oncology with
us. Join our East Coast team.
Learn More



RESILIENT TOGETHER

Learn more about our journey of progress for
patients and our efforts to translate drug discovery
and development into breakthrough medicines.

Learn More



CANCER IS OUR CAUSE

We strive to develop effective, tolerable and durable
treatments to help patients with cancer thrive.

Learn More
Featured Patient Story All Videos


TACKLING DIFFICULT-TO-TREAT CANCERS

To date, we have three medicines available to treat certain types of kidney,
liver and thyroid cancers and advanced melanoma.

About Our Medicines



COMPANY STATEMENT ON COVID-19

Exelixis is actively monitoring the global COVID-19 pandemic, and remains
steadfast in our commitment to the health and safety of our patients, customers,
employees and local communities.

READ MORE


FEATURED NEWS

ALL NEWS
 * 09/09/2022
   Exelixis Announces Dose-Escalation Results from the Phase 1 STELLAR-001 Trial
   Evaluating XL092 Alone and in Combination with an Immune Checkpoint Inhibitor
   in Patients with Advanced Solid Tumors at ESMO 2022
   Read More
 * 09/07/2022
   Exelixis Announces Detailed Results from Phase 3 COSMIC-313 Pivotal Trial in
   Patients with Previously Untreated Advanced Kidney Cancer at ESMO 2022
   Read More
 * 09/06/2022
   Exelixis To Webcast Fireside Chats as Part of Investor Conferences in
   September
   Read More


RECENT EVENTS

ALL EVENTS
   
 * 09.15.2022
   September 15, 2022 9:10 AM EDT : BofA Securities Global Healthcare Conference
   2022
   View Event
 * 09.13.2022
   September 13, 2022 4:05 PM EDT : Morgan Stanley 20th Annual Global Healthcare
   Conference
   View Event

OUR STORY

 * Mission
 * Leadership
 * Board of Directors
 * Collaborations

MEDICINES

 * Our Medicines
 * Access

RESEARCH & DEVELOPMENT

 * Research & Development
 * Pipeline
 * Clinical Trials

IMPACT

 * Why Cancer?
 * Patient Stories
 * Grants & Giving
 * Corporate Responsibility
 * Environmental, Social & Governance
 * Statement on COVID-19

INVESTORS & MEDIA

 * Investors Overview
 * News & Events
 * Stock Information
 * Financial Information
 * Investor Resources
 * Corporate Governance
 * Contact IR

 * Our Story
   * Mission
   * Leadership
   * Board of Directors
   * Collaborations
 * Medicines
   * Our Medicines
   * Access
 * Research & Development
   * Research and Development
   * Pipeline
     * Pipeline Overview
     * Early-Stage Compounds
     * Cabozantinib Pipeline
     * Other Partnered Programs
   * Clinical Trials
 * Impact
   * Why Cancer?
   * Patient Stories
   * Grants & Giving
   * Corporate Responsibility
   * Environmental, Social & Governance
   * Statement on COVID-19
 * Investors & Media
   * Investors Overview
   * News and Events
     * Press Releases
     * Event Calendar
     * Media Resources
   * Stock Information
     * Stock Quote & Chart
     * Historical Price Lookup
     * Investment Calculator
     * Analyst Coverage
     * Earnings Estimates
   * Financial Information
     * Annual Reports
     * SEC Filings
     * Interactive Analyst Center
   * Investor Resources
     * Investor FAQs
     * Information Request
   * Corporate Governance
     * Corporate Governance Documents and Information
     * Management
     * Board of Directors
     * Committee Composition and Charters
   * Contact IR
 * 
 * Careers
 * Contact Us
 * 

 * Facebook
 * Twitter
 * 
   

© Exelixis, Inc. 2022
 * Ethics & Compliance
 * Privacy
 * Terms of Use

 * Facebook
 * Twitter
 * 
   

This website uses cookies to improve and personalize content and for tracking
and analytics. You can learn more from our Privacy Statement.

OK